Andreas Möller,
Associate Professor,
Group Leader and Head, Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute
Dr. Andreas Möller is Group Leader of the Tumour Microenvironment Laboratory at the QIMR Berghofer Medical Research Institute, Brisbane, Australia. He is also adjunct Associate Professor with the Faculty of Medicine at the University of Queensland, and the School of Biomedical Science at the Queensland University of Technology. Dr Möller received his doctoral training at the German Cancer Research Centre (DKFZ) in Heidelberg, Germany, followed by postdoctoral training at the University of Berne, Switzerland, and the Peter MacCallum Cancer Center, Melbourne, Australia. Dr Möller is an expert in cancer metastasis and cancer immunology, and now has more than 10 years of experience in the Extracellular Vesicle (EV) field. Based on clinical collaborations, patents in the EV field and commercial partners, his work is focused on gaining a better understanding of the role of EVs in cancer progression and their use as cancer biomarkers.
Function and Clinical Utility of Cancer-derived Extracellular Vesicles
Wednesday, 2 March 2022 at 15:00
Add to Calendar ▼2022-03-02 15:00:002022-03-02 16:00:00Europe/LondonFunction and Clinical Utility of Cancer-derived Extracellular VesiclesCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Late diagnosis and lack of reliable prognostic outcome predictions are important unmet clinical needs. Reasons for our inability to generate reliable diagnostic, prognostic and/or predictive biomarkers are the incomplete understanding of cancer progression, especially metastatic spread. For a cancer to spread from the primary site to distant organs, a large number of essential steps have to be overcome. We, and others, showed that cancer-secreted factors, including extracellular vesicles (EVs), are mediators of creating immune-suppressed, permissive environments (pre-metastatic niches) at distant organs before the arrival of cancer cells. In this presentation, I will summarize the research approaches in the area of cancer-derived EVs undertaken by my group. I will discuss novel data on how cancer-derived EVs can specifically distribute to certain organs in the body, depending on the tumor microenvironment of the primary tumors. These modifications increase pre-metastatic niche formation and metastatic spread. Analyzing the content of cancer-derived EVs, I will additionally show intriguing clinical data on how the content of plasma EVs can be used to diagnose cancer in the first place and then to predict the outcome of a patient at baseline.
Add to Calendar ▼2022-03-01 00:00:002022-03-02 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-03-02 15:00:002022-03-02 16:00:00Europe/LondonFunction and Clinical Utility of Cancer-derived Extracellular VesiclesCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
